The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter phase I trial of sorafenib (S) in high-risk hepatocellular carcinoma (HCC) patients after liver transplantation (LT).
Abby B. Siegel
Research Funding - Bayer/Onyx
Anthony B. El-Khoueiry
Consultant or Advisory Role - Bayer/Onyx
Research Funding - Bayer/Onyx
Richard S. Finn
Consultant or Advisory Role - Bayer/Onyx
Abhishek Goyal
No relevant relationships to disclose
Charles David Blanke
No relevant relationships to disclose
Robert S. Brown
No relevant relationships to disclose